Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All remdesivir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 5% Improvement Relative Risk Non-ventilated patients 14% Remdesivir  SOLIDARITY  LATE TREATMENT  RCT Is late treatment with remdesivir beneficial for COVID-19? RCT 5,451 patients in multiple countries No significant difference in mortality c19early.org SOLIDARITY Trial Consortium, NEJM, Oct 2020 Favors remdesivir Favors control

Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results

SOLIDARITY Trial Consortium, NEJM, doi:10.1056/NEJMoa2023184 (date from preprint), SOLIDARITY, NCT04315948
Oct 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
WHO SOLIDARITY open-label RCT with 2,750 very late stage (76% on oxygen/ventilation) remdesivir patients, mortality relative risk RR 0.95 [0.81-1.11], p=0.50. Non-ventilated patients show a greater benefit, RR 0.86 [0.72-1.04], p = 0.13.
Gérard, Wu, Zhou show significantly increased risk of acute kidney injury with remdesivir.
Study covers remdesivir and HCQ.
risk of death, 5.0% lower, RR 0.95, p = 0.53, treatment 301 of 2,743 (11.0%), control 303 of 2,708 (11.2%), NNT 464, day 28.
non-ventilated patients, 14.0% lower, RR 0.86, p = 0.13, day 28.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
SOLIDARITY Trial Consortium et al., 15 Oct 2020, Randomized Controlled Trial, multiple countries, peer-reviewed, 15 authors, trial NCT04315948 (history) (SOLIDARITY).
This PaperRemdesivirAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.10.15.20209817.this version posted October 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. 1 MedRxiv (October 15) version Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results WHO Solidarity trial consortium* *A complete list of SOLIDARITY Trial investigators is provided in the Supplementary Appendix. Hongchao Pan, Ph.D., Richard Peto, F.R.S., Quarraisha Abdool Karim, Ph.D., Marissa Alejandria M.D., M.Sc., Ana Maria HenaoRestrepo, M.D., M.Sc., César Hernández García M.D., Ph.D., Marie-Paule Kieny Ph.D., Reza Malekzadeh M.D., Srinivas Murthy M.D. C.M., Marie-Pierre Preziosi M.D., Ph.D., Srinath Reddy M.D., D.M., Mirta Roses Periago M. D., Vasee Sathiyamoorthy B.M.B.Ch., Ph.D., John-Arne Røttingen M.D., Ph.D., and Soumya Swaminathan M.D. , as the members of the Writing Committee, assume responsibility for the content and integrity of this article. International Steering Committee *National PI; †National Coordinator; ‡Executive Group;§Discovery add-on study. Albania: University Hospital Centre, Tirana N Como*; National Agency for Medicines and Medical Devices N Sinani†. Argentina: Fundación del Centro de Estudios Infectológicos G Lopardo*; National Academy of Sciences of Buenos Aires M Roses Periago†‡. Austria:§. Belgium:§. Brazil: Oswaldo Cruz Foundation EP Nunes*, PPS Reges†. Canada: University of British Columbia S Murthy*‡; Public Health Agency of Canada M Salvadori†. Colombia: National University of Colombia CA Alvarez- Moreno*; Ministry of Health ML Mesa Rubio†. Egypt: National Hepatology and Tropical Medicine Research Institute M Hassany*; Ministry of Health and population H Zaid†. Finland: Helsinki University Hospital and South Karelian Central Hospital, Lappeenranta KAO Tikkinen*; Finnish Institute for Health and Welfare and University of Finland, Helsinki M Perola†. France: Hospices Civils de Lyon, Lyon F Ader*§; Institut National de la Santé Et de la Recherche Médicale, Paris MP Kieny†‡§. Honduras: National Autonomous University of Honduras MT Medina*; Secretaria de Salud de Honduras N Cerrato†. India: ICMR National AIDS Research Institute, Pune S Godbole*†; Public Health Foundation of India KS Reddy‡. Indonesia: National Institute of Health Research and Development I Irmansyah*; RSUP Persahabatan, Jakarta MR Rasmin†. Iran (Islamic Republic of): Digestive Disease Research Institute, Teheran University of Medical Sciences, Tehran R Malekzadeh*†‡. Ireland: HRB Clinical Research Facility, University College, Cork J Eustace*; Department of Health T Maguire†. Italy: University of Verona E Tacconelli*; Italian Medicines Agency N Magrini†. Kuwait: Infectious Diseases Hospital A Alhasawi*; Ministry of Health A Al-Bader†. Lebanon: Rafic Hariri University Hospital P Abi Hanna*; Ministry of Public Health R Hamra†. Luxembourg:§. Lithuania: University Hospital Santaros klinikos, Vilnius L Jancoriene*, L Griskevicius†. Malaysia: Penang Hospital TS Chow*; Hospital Sungai Buloh, Jalan Hospital S Kumar†. North Macedonia: University Clinic of Infectious Diseases and Febrile Conditions M Stevanovikj*; Ministry of Health S Manevska†. Norway: Oslo University Hospital P Aukrust*, A Barratt-Due†; Research Council of Norway JA Røttingen‡. Pakistan: Shaukat Khanum Memorial Cancer..
{ 'DOI': '10.1056/nejmoa2023184', 'ISSN': ['0028-4793', '1533-4406'], 'URL': 'http://dx.doi.org/10.1056/NEJMoa2023184', 'alternative-id': ['10.1056/NEJMoa2023184'], 'author': [{'affiliation': [], 'name': 'WHO Solidarity Trial Consortium', 'sequence': 'first'}], 'container-title': 'New England Journal of Medicine', 'container-title-short': 'N Engl J Med', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2020, 12, 2]], 'date-time': '2020-12-02T22:03:18Z', 'timestamp': 1606946598000}, 'deposited': { 'date-parts': [[2023, 8, 10]], 'date-time': '2023-08-10T18:05:51Z', 'timestamp': 1691690751000}, 'funder': [ { 'DOI': '10.13039/100004423', 'doi-asserted-by': 'publisher', 'name': 'World Health Organization'}], 'indexed': {'date-parts': [[2024, 4, 7]], 'date-time': '2024-04-07T23:13:51Z', 'timestamp': 1712531631524}, 'is-referenced-by-count': 1670, 'issue': '6', 'issued': {'date-parts': [[2021, 2, 11]]}, 'journal-issue': {'issue': '6', 'published-print': {'date-parts': [[2021, 2, 11]]}}, 'language': 'en', 'license': [ { 'URL': 'http://www.nejmgroup.org/legal/terms-of-use.htm', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2021, 2, 11]], 'date-time': '2021-02-11T00:00:00Z', 'timestamp': 1613001600000}}], 'link': [ { 'URL': 'http://www.nejm.org/doi/pdf/10.1056/NEJMoa2023184', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '150', 'original-title': [], 'page': '497-511', 'prefix': '10.1056', 'published': {'date-parts': [[2021, 2, 11]]}, 'published-print': {'date-parts': [[2021, 2, 11]]}, 'publisher': 'Massachusetts Medical Society', 'reference': [ {'DOI': '10.1371/journal.pmed.1003252', 'doi-asserted-by': 'publisher', 'key': 'r4'}, {'DOI': '10.1016/S0140-6736(05)66544-0', 'doi-asserted-by': 'publisher', 'key': 'r5'}, {'DOI': '10.1056/NEJMoa2007764', 'doi-asserted-by': 'publisher', 'key': 'r6'}, {'DOI': '10.1016/S0140-6736(20)31022-9', 'doi-asserted-by': 'publisher', 'key': 'r7'}, {'DOI': '10.1001/jama.2020.16349', 'doi-asserted-by': 'publisher', 'key': 'r8'}, {'DOI': '10.1056/NEJMoa2015301', 'doi-asserted-by': 'publisher', 'key': 'r9'}, {'DOI': '10.1038/bjc.2011.79', 'doi-asserted-by': 'publisher', 'key': 'r10'}, {'DOI': '10.1056/NEJMoa2022926', 'doi-asserted-by': 'publisher', 'key': 'r12'}, {'DOI': '10.1016/S0140-6736(20)32013-4', 'doi-asserted-by': 'publisher', 'key': 'r13'}, {'DOI': '10.1056/NEJMoa2001282', 'doi-asserted-by': 'publisher', 'key': 'r15'}, {'DOI': '10.1016/j.antiviral.2020.104866', 'doi-asserted-by': 'publisher', 'key': 'r16'}, {'DOI': '10.1093/jac/dkaa195', 'doi-asserted-by': 'publisher', 'key': 'r17'}, {'DOI': '10.1089/10799900050163226', 'doi-asserted-by': 'publisher', 'key': 'r18'}, {'DOI': '10.1186/s13054-020-03048-5', 'doi-asserted-by': 'publisher', 'key': 'r19'}, {'DOI': '10.1007/s00134-020-06086-3', 'doi-asserted-by': 'publisher', 'key': 'r20'}, {'DOI': '10.1128/MCB.00146-10', 'doi-asserted-by': 'publisher', 'key': 'r21'}, {'DOI': '10.1056/NEJMoa2021436', 'doi-asserted-by': 'publisher', 'key': 'r22'}], 'reference-count': 17, 'references-count': 17, 'relation': { 'has-preprint': [ { 'asserted-by': 'object', 'id': '10.1101/2020.10.15.20209817', 'id-type': 'doi'}]}, 'resource': {'primary': {'URL': 'http://www.nejm.org/doi/10.1056/NEJMoa2023184'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['General Medicine'], 'subtitle': [], 'title': 'Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results', 'type': 'journal-article', 'volume': '384'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit